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Abstract 
Objective: Alzheimer’s disease (AD) is considered an age-related disorder. However, it is unclear if 
AD induces the same pathological and neurophysiological modifications in synaptic functions 
independently from age of disease onset. We used transcranial magnetic stimulation tools to investigate 
the mechanisms of cortical plasticity and sensory-motor integration in AD patients with a wide range of 
disease onset. 
Methods: We evaluated newly diagnosed sporadic AD (n=54) in comparison with healthy age-
matched controls (HS n=24). Cortical plasticity mechanisms of long-term potentiation (LTP) or of 
long-term depression (LTD) were assessed using respectively intermittent (iTBS) or continuous theta 
burst stimulation (cTBS) protocols. Sensory-motor integration was evaluated by means of short 
afferent inhibition (SAI) protocol.  
Results: AD patients show after iTBS an impairment of LTP-like cortical plasticity forming a 
paradoxical LTD in comparison to HS. LTD-like cortical plasticity is similar between AD and HS. 
LTP-like cortical plasticity is not associated with age, but AD patients presenting with more altered 
LTP-like cortical plasticity have more severe cognitive decline at 18 months. SAI is impaired in AD 
and shows a strong association with the individual age of subjects rather than with disease age of onset.  
Interpretation:  Cortical LTP disruption is a central mechanism of AD that is independent from age of 
onset. AD can be described primarily as a disorder of LTP-like cortical plasticity not influenced by 
physiological ageing and associated with a more severe cognitive decline. 
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Introduction 
Albeit typically considered an age-related disorder, in the last years there has been a growing interest in 
the early detection of Alzheimer’s disease (AD) with the development of new biomarkers and genetic 
techniques. This increasingly awareness about Early Onset Alzheimer’s Disease (EOAD) is raising 
from demographic and social issues, since these patients start to complain their first cognitive 
symptoms when they still are a mainstay within the society, thus representing a huge burden to health 
and economic system. EOAD conventionally indicates patients with onset of AD before 65 years of 
age1, while AD patients with a more common disease onset >65 years of age can be classified as Late 
Onset AD (LOAD)1. Despite pathological studies seem to indicate that EOAD and LOAD share the 
same features and represent a continuum of the same pathological process, it is still debated whether 
EOAD and LOAD clinically manifest the same neuropsychological symptoms2, 3, 4, 5 or are 
characterized by the same imaging patterns6, 7, 8. However, this cutoff point is considered arbitrary since 
it is rather due to sociological/demographic aspects and it has no specific biological significance.1 
In the recent years transcranial magnetic stimulation (TMS) has been employed to investigate key 
neurophysiologic and pathophysiologic aspects of AD patients in vivo9, 10, 11. Several studies using 
TMS have claimed the presence of abnormalities in cortical reactivity, plasticity and connectivity in 
AD patients. One of the most consistent finding is a relative impairment of short-latency afferent 
inhibition (SAI), a protocol that measures sensory-motor integration that is partially mediated by 
central cholinergic transmission and it is commonly found altered in patients with AD12. Nevertheless, 
SAI is known to be reduced by aging in healthy controls13, 14, thereby questioning whether this 
neurophysiological marker may be specific for AD. Recently, abnormalities of cortical plasticity have 
been demonstrated in AD using repetitive TMS. These studies were based on the strong evidence 
obtained by electrophysiological recordings in AD animal models15, 16 showing that cortical plasticity is 
dampened by Aβ peptides and tau proteins; in particular these molecules are able to disrupt 
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hippocampal long-term potentiation (LTP), an electrophysiological correlate of learning and memory 
and to increase long term depression (LTD), which has been related to increased apoptosis15, 16. 
According to this background, we recently found, using protocols of theta burst stimulation (TBS), that 
LTP-like cortical plasticity is abolished or even pathologically reverted towards LTD in AD patients, 
while LTD is preserved or even enhanced11,17. Here we used these TMS methods to compare 
neurophysiological markers of sensory-motor integration (assessed by SAI) and cortical plasticity 
(assessed by TBS) in AD patients with a wide range of disease onset, from early to late age of onset. 
We hypothesized that altered cortical plasticity should be a common feature of AD independently from 
age of onset, while the impairment of SAI would be more sensitive to the underlying mechanisms of 
aging13, 14.    
 
Methods 
Subjects 
Fifty-four consecutive patients (ranged 55-80 years, median 68.5) were recruited at the memory clinic 
of the University Hospital Tor Vergata, admitted for complaining memory symptoms. Patients fulfilled 
the clinical criteria of dementia as defined by the DSM-IV and probable or possible AD according to 
the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer’s disease and Related Disorders Association18. Disease duration was calculated using 
standardized semi structured questions19. After the first visit to our Centre, all patients underwent for 
diagnostic purposes a complete clinical investigation in a period not superior to 60 days, including 
medical history, neurological examination, Mini-Mental State Examination (MMSE), a complete blood 
screening, neuropsychological assessment including the following cognitive domains: general cognitive 
efficiency: MMSE20,21; verbal episodic long-term memory: Rey auditory verbal long term memory (15-
Word List Immediate and 15-min Delayed recall)22; visuo-spatial abilities and visuo-spatial episodic 
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long-term memory: Complex Rey’s Figure (copy and 10-min Delayed recall)23; executive functions: 
phonological word fluency24; analogic reasoning: Raven’s Colored Progressive Matrices24. Patients 
underwent also a neuropsychiatric evaluation, magnetic resonance or CT imaging, PET/CT, and lumbar 
puncture for CSF analysis (Table 1). Exclusion criteria were the following: patients with isolated 
deficits, with clinically manifest acute stroke in the last 6 months showing a Hachinsky scale score >4, 
and a radiological evidence of ischemic lesions, Aβ1-42 CSF values >600 pg/mL.  
Neurophysiological examinations were performed at the Santa Lucia Foundation within 30 days from 
CSF sampling. In the 90 days prior to TMS evaluation, none of the patients were treated with drugs that 
could have modulated cerebral cortex excitability such as Acetylcholinesterase inhibitors (AChEI)10, 
antidepressants or any other neuroactive drugs (i.e. benzodiazepines, anti-epileptic drugs or 
neuroleptics). After the neurophysiological assessment all patients started treatment with rivastigmine 
patch (n=26) or donepezil (n=28) and were followed longitudinally with clinical assessments and 
MMSE testing at 6, 12 and 18 months. Twenty-four age, sex- and education-matched healthy subjects 
(HS) (ranged 58-73 years, median 67) were recruited as controls. All participants or their legal 
guardian provided written informed consent after receiving an extensive description of the study. The 
study was performed according to the Declaration of Helsinki. The ethics committee of the Santa Lucia 
Foundation IRCSS approved this protocol (Prot. CE/AG4/PROG.392-08). 
 
CSF biomarkers analysis  
The first 12 mL of CSF were collected in a polypropylene tube and directly transported to the local 
laboratory for centrifugation at 2000×g at +4°C for 10 minutes. The supernatant was pipetted off, 
gently stirred and mixed to avoid potential gradient effects, and aliquoted in 1 mL portions in 
polypropylene tubes that were stored at −80°C pending biochemical analyses, without being thawed 
and re-frozen. CSF t-tau and p-tau phosphorylated at Thr181 concentrations were determined using a 
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sandwich ELISA (Innotest hTAU-Ag, Innogenetics, Gent, Belgium). Aβ1-42 levels were determined 
using a sandwich ELISA (Innotest® ß- amyloid (1–42), Innogenetics, Gent, Belgium), specifically 
constructed to measure Aβ-amyloid containing both the first and 42nd amino-acid, as previously 
described25. 
 
Transcranial magnetic stimulation 
All patients and healthy controls underwent continuous TBS (cTBS), intermittent TBS (iTBS) and SAI 
protocols in three different sessions, with at least a three day interval between each session. The order 
of the sessions was pseudo-randomized across patients and healthy controls. Motor evoked potentials 
(MEP) were recorded from the right first dorsal interosseous muscle using 9 mm diameter, Ag–AgCl 
surface cup electrodes. Responses were amplified with a Digitimer D360 amplifier (Digitimer Ltd, UK) 
and filtered (20 Hz-2 kHz), then recorded by computer using SIGNAL software with a sampling rate of 
5 kHz per channel (Cambridge Electronic Devices, UK). A monophasic Magstim 200 device (Magstim 
Co, UK) was used to define the motor hot spot and to assess MEP size using standard 70 mm figure-of-
eight shaped coil. The motor hot-spot was defined as the location where monophasic TMS pulses 
consistently produced the largest MEP size at 120% of resting motor threshold (RMT) in the target 
muscle. RMT was defined as the minimum stimulus intensity that produced motor evoked response of 
50 µV in at least 5 of 10 trials at rest26. 
A second coil was connected to a biphasic Super Rapid Magstim stimulator (Magstim Co, UK) to 
deliver TBS. The active motor threshold (AMT) was defined as the minimum stimulus intensity that 
produced a liminal motor evoked response (about 200 μV in 50% of trials) during isometric contraction 
of the tested muscle at about 10% of maximum force as measured through a manual transducer. 
In the cTBS protocol bursts at 80% AMT were repeated at 5 Hz (i.e. every 200 milliseconds), while 
each burst consisted of three stimuli repeating at 50 Hz, for 40 seconds (600 pulses). In the iTBS 
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protocol, a 2 second train of TBS was repeated 20 times, every 10 seconds for a total of 190 seconds 
(600 pulses)27. The  iTBS and cTBS protocols were tested after a period of relaxation of the target 
muscle. The change in corticospinal excitability produced by each intervention was assessed by 
measuring the amplitude of the MEP response to a standard test pulse that remained constant 
throughout the experiment. In each subject the intensity of the test pulse was individually adjusted at 
the start of the experiment to produce a stable MEP of 1 mV with the subject at rest. Twenty MEPs 
were collected and averaged at baseline. Then, over the same hot-spot, twenty MEPs were recorded at 
1-5, 6-10, 11-15, 16-20 and 21-25 minutes after TBS and averaged. The inter-trial interval was set at 5 
seconds (±10%) for  individual MEPs within each block. 
SAI was studied using the technique that has been recently described28, 29. Conditioning stimuli were 
single pulses (200 μs) of electrical stimulation applied through bipolar electrodes to the right median 
nerve at the wrist (cathode proximal). The intensity of the conditioning stimulus was set at just over 
motor threshold for evoking a visible twitch of the thenar muscles. The intensity of the test cortical 
magnetic stimulus was adjusted to evoke a MEP in the relaxed right first dorsal interosseous with 
amplitude of approximately 1 mV peak to peak. For N20 recordings cup electrodes were placed over 
the centroparietal contralateral position keeping the Fz as the reference (International 10–20 system). 
Electrical median nerve stimulation was applied at the right wrist at 2 Hz. The latency of the N20  
component of somatosensory evoked potential was determined by averaging 200 trials.  The 
conditioning stimuli to the peripheral nerve preceded the magnetic test stimulus by different 
interstimulus intervals (ISIs), ranging from -4 to +8 milliseconds from the N20 in steps of 4 
milliseconds30. Ten paired stimuli were delivered at each ISI. The subject was given audiovisual 
feedback at high gain to assist in maintaining complete relaxation. The inter-trial interval was set at 5 
seconds (±10%), for a total duration of approximately five minutes. Measurements were made on each 
individual trial. The mean peak-to peak amplitude of the conditioned motor evoked potential at each 
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ISI was expressed as a percentage of the mean peak-to-peak amplitude size of the unconditioned test 
pulse in that block. 
 
Data analysis 
Data were analyzed using SPSS for Windows version 11.0. For TMS experiments, two-way repeated 
measure ANOVAs were performed on MEP amplitude expressed as percentage of change in 
comparison to baseline for each TBS protocol (cTBS and iTBS) with TIME (1–5, 6–10, 11–15,16–20, 
and 21–25 min after TBS) as within subjects factors and GROUP (AD and HS) as between subjects 
factor.  For SAI the electrophysiological parameters of AD patients were compared by means of 
repeated measures ANOVA with ISI (−4, 0, +4 and +8 milliseconds plus the latency of the N20) as 
within subject factors and GROUP (AD and HS) as between subjects factor. The Greenhouse-Geisser 
correction was used for non-spherical data. Mauchley’s test examined for sphericity. When a 
significant main effect was reached, paired t-tests with Bonferroni correction were employed to 
characterize the different effects of the specific ISIs. Pearson’s r coefficient was first used in univariate 
correlations in order to explore any influence the age could have on the individual amount of mean 
change across all time intervals induced by the iTBS and cTBS protocols and by SAI protocol at 
ISI=+4 in all subjects (AD patients and HS). In a second step, a multiple linear regression model was 
constructed for each protocol (iTBS, cTBS, SAI) to better characterize the relationship between each 
neurophysiological measure with age and disease as covariates in all subjects (AD patients and HS). 
We also performed Spearman only in AD patients correlation analyses between cognitive decline (delta 
score with baseline evaluation) and iTBS and cTBS induced cortical plasticity (individual mean value) 
and SAI protocol at ISI=+4. Furthermore, a multiple linear regression analysis was constructed in AD 
patients for each neurophysiological parameter (iTBS, cTBS, SAI) to determine their association with 
age, cognitive decline and disease duration. Correlation analyses were corrected for multiple 
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comparisons.  Coefficients with standard error (SE), and 95% confidence interval (CI) were provided. 
A p value of < 0.05 was considered statistically significant.  
 
Results 
Transcranial magnetic stimulation 
The TMS procedures were well tolerated in all subjects. RMT to TMS (mean±standard deviation (SD)) 
was lower in AD patients in comparison with HS (AD: 37.2±0.93%; HS: 42.2±1.09%; p=0.003). 
Baseline mean MEP amplitude did not differ between AD patients and HS across all protocols (AD: 
1.12±0.43 mV; HS: 1.15±0.34 mV). 
For the iTBS protocol, AD patients showed an altered LTP-like cortical plasticity, with a reversal of 
LTP-like cortical plasticity towards LTD in comparison with HS: there was an effect for the GROUP 
(F(1,76)=63.72, p=0.000001) and for the TIME (F(4,304)=2.63, p=0.034) main factors; the interaction 
GROUP x TIME was also significant (F(4,304)=6.63, p=0.00004). Post-hoc analysis with Bonferroni 
correction showed that AD patients differed form HS at 10, 15, 20 and 25 minutes time point (all 
p<0.001) (Figure 1). For the cTBS protocol the repeated measure ANOVA performed on the 
percentage changes of the mean MEP amplitude did not show any effect for the GROUP 
(F(1,64)=0.12, p=0.96), for the TIME main factor (F(4,256)=0.97, p=0.42) and for the GROUP x 
TIME interaction (F(4,256)=0.66, p=0.61) (Figure 2). The ANOVA analysis performed on SAI 
measurements showed an effect for the GROUP (F(1,75)=5.29, p=0.02) and ISI main factor 
(F(3,225)=46.58, p=0.00001), but not a GROUP x ISI interaction (F(3,225)=0.32, p=0.80) (Figure 3).  
Correlations analyses performed to explore any influence the age could have on the neurophysiological 
parameters did not show any correlation for iTBS (Figure 4A) and cTBS (Figure 4B) with age; on the 
other hand, we found that age correlated positively with the impairment of SAI (r= 0.53; p=0.001) 
(Figure 4C).  
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These results were confirmed by multiple linear regression analyses showing a strong association 
between iTBS induced cortical plasticity and diagnosis of AD, but no association with age. We did not 
find any association for cTBS induced cortical plasticity with any of the covariates. On the other hand, 
we found that SAI values were strongly associated with age and weakly with diagnosis of AD (Table 
2). 
 
Clinical follow-up  
MMSE scores performed at follow up evaluations were 21.43±0.67 (mean±SD) at 6 months, 
20.14±0.85 at 12 months and 18.21±0.91 at 18 months. AD patients underwent a substantial cognitive 
decline as confirmed by ANOVA showing an effect for the TIME main factor (F(3,156)=16.953, 
p<0.001). Post-hoc analysis with Bonferroni correction showed that MMSE scores differed from 
baseline at 18 months follow up evaluation (p<0.001). Correlation analyses between cognitive decline 
(computed as delta score with baseline evaluation) and neurophysiological parameters (iTBS, cTBS 
and SAI) showed that AD patients presenting with more altered iTBS induced cortical plasticity had 
more severe cognitive decline at 18 months (r=0.30; p=0.020) (Figure 5A). We did not found any 
correlations for cTBS (Figure 5B) and SAI (Figure 5C) values. These results were further confirmed 
by multiple linear regression analyses showing a significant association between iTBS induced cortical 
plasticity and cognitive decline, at equal values of age and disease duration. We did not find any 
association for cTBS induced cortical plasticity. On the contrary, SAI values were not associated with 
cognitive decline but only with age (Table 3). 
 
 
 
11 
 
Discussion 
We provide novel evidence that AD patients constantly tend to form LTD instead of LTP 
independently from age of disease onset. Notably, more altered LTP-like cortical plasticity is 
associated in AD patients with more severe cognitive decline at 18 months follow-up. On the other 
hand, SAI sensibly declines with age in both AD patients and healthy controls and it is not associated 
with cognitive decline at 18 months follow-up in AD patients.  
Taken together, these results provide a compelling proof that in AD patients the LTP-like cortical 
plasticity machinery is already deeply dampened even when the disease occurs earlier, while sensory-
motor integration is relatively spared. On the other hand, when the disease occurs later there is a clear 
impairment of both LTP-like cortical plasticity and SAI signaling. Thereby, we propose that LTP-like 
cortical plasticity is a core neurophysiological marker of AD-related dysfunction, clearly differentiating 
AD patients from healthy individuals independently from age of disease onset. 
The current findings are supported by recent works consistently demonstrating that AD patients are 
characterized by abnormalities of LTP-like cortical plasticity11,12,31,32. Notably these results are in most 
cases superimposable to experimental electrophysiological recordings obtained from animal models of 
AD15, 16, 33 revealing that both tau oligomers and amyloid peptides, the neuropathological hallmarks of 
AD pathology, are able to disrupt the processes occurring for a stable synaptic efficacy34, 35. These 
pathological mechanisms induce on one hand a weakened hippocampal and cortical LTP and on the 
other a more robust LTD36, a process related to apoptosis and degeneration. Interestingly, molecular 
studies showed that beta and tau pathology trigger a structural synaptic remodeling by forcing pro-
apoptotic cell pathways, inducing a burdened effective synaptic activity37. The progressive reduction of 
synaptic connections caused by the shrinkage of dendritic spines can be recorded with 
electrophysiological tools in vitro as imbalances of the physiological forms of long-term modifications 
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between networks of neurons establishing a high-order functional net38, driving a marked propensity to 
form a more pronounced LTD plasticity.   
At this regard, we recently found that AD patients with more pathological CSF tau levels are 
characterized by a stronger tendency to form LTD and that this neurophysiological biomarker is related 
to a more aggressive clinical course, implying that an altered cortical plasticity, eventually caused by 
tau pathology, is strictly linked to the underlying clinical progression of AD39. Together with the 
current findings, these data indicate that, although tested in the motor cortex, rTMS can be considered a 
reliable tool to examine cortical plasticity in AD patients in analogy with hippocampal plasticity 
assessed in animal models of AD. 
We did not find any correlation between SAI values and clinical worsening; on the contrary, LTP 
impairment correlates positively with clinical worsening overall in AD patients, strengthening the 
hypothesis of LTP disruption as key neurophysiological biomarker for both the pathogenesis and 
clinical progression of Alzheimer’s disease, while SAI seems to reflect the physiological processes of 
ageing. Our findings are strengthened by several clinical and experimental evidence tracking 
cholinergic modifications during both physiological40, 41 and pathological aging processes42, 43, 44. Basal 
forebrain cholinergic complex, critical for cognitive functions in humans by sprouting synaptic contacts 
in high-order cortical networks, is characterized by a selective neuronal vulnerability and during ageing 
is easily susceptible to undergo degenerative changes, resulting in cholinergic hypofunction45. 
SAI efficacy has been shown to be linked to cholinergic transmission10 and since it is selectively 
altered in AD patients9, it has been interpreted as measure of central cholinergic dysfunction, historical 
neurochemical marker of AD. Intriguingly, recent works showed a specific age-dependent alteration in 
the cortical circuits mediating SAI in the motor cortex of healthy subjects13, 14. These results led us to 
conclude that the main electrophysiological marker of AD is the deep and early impairment of cortical 
plasticity machinery, whereas central cholinergic dysfunction could be secondary to a process in which 
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the physiological aging process takes part, and is likely accelerated by concomitant neural degeneration 
process.  
The selective weakening of cortical plasticity mechanisms showed by AD patients, differently from 
SAI, gives new interesting insights also for a therapeutic approach: so far, most of the attention has 
been driven onto improving of cholinergic transmission, and actually AChEI represent the only 
pharmacological class approved for treatment of AD symptoms, although its scarce and short-lasting 
effects. On the other hand, the data presented here highlight the specificity of LTP impairment as 
marker of pathophysiological dysfunction in AD and, as such, it should be taken in account also for the 
adoption of new pharmacological strategies considering AD as a disorder of synaptic plasticity and 
related transmitters system. This view could promote novel drugs able to influence positively synaptic 
plasticity, such as dopamine, a strong neuromodulator of neuroplasticity in both healthy subjects 46 and 
AD patients17. 
In conclusion, our data show that LTP mechanisms are altered in AD patients independently from age 
of disease onset. LTP impairment is AD-dependent, and could be considered as a neurophysiological 
marker of disease, while the SAI dysfunction is age-dependent thus representing more likely a marker 
of the interaction between physiological and pathological ageing47. 
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Figure Legends 
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Legend to Figure 1. After effects of iTBS protocol on MEP amplitude in AD and HS. * indicate 
p<0.05. Error bars indicate SEM. 
Legend to Figure 2. After effects of cTBS protocol on MEP amplitude in AD and HS. Error bars 
indicate SEM. 
Legend to Figure 3. Changes in MEP amplitude for the SAI protocol in AD and HS. * indicate 
p<0.05. Error bars indicate SEM. 
Legend to Figure 4. Pearson’s r correlation matrices between the age and individual amount of 
mean change in MEP amplitude induced by iTBS (A) and cTBS (B), and SAI (C) protocol in 
healthy subjects and AD patients.  
Legend to Figure 5.  Spearman correlation matrices in all AD patients between the individual amount 
of mean change in MEP amplitude induced by iTBS (A), cTBS (B) and and SAI (C) protocol and the 
cognitive progression expressed in delta MMSE scores at 18 months follow up. 
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Table 1. Demographic and clinical characteristics of AD patients and Healthy Subjects. 
 
 
 
Abbreviations: n=numbers; y=years; m=months; C.I. = confidence interval; CSF= Cerebrospinal Fluid; 
CDR=Clinical Dementia Rating; ADL=Activities of Daily Living; IADL=Instrumental Activities of 
Daily Living n.a.= not applicable; a=Student t-test; b=Fisher’s exact test. C.I. for continuous variables 
were calculated on differences between means. C.I for dichotomous variables were calculated on odds 
ratios. 
 AD (n=54) HS (n=24) p 95% C.I. 
Age at baseline, y    
(mean±SD)a 
67.9±0.8 66.2±1.0 0.19 -4.74 – 0.97 
Female (%)b 48 50 1.00 0.35 – 2.43 
Formal education, y 
(mean±SD)a 
8.7±4.4 9.4±4.2 0.79 -1.91 – 2.48 
Diabetes (%)b 17 20 0.75 0.22 – 2.57 
Hypertension (%)b 39 33 0.45 0.55 – 4.36 
Hpercolesterolemia 
(%)b 
18 20 0.75 0.22 – 2.57 
Head injury (%)b 0 0 1.00 n.a. 
CSF Beta 1-42 
pg/mL(mean±SD) 
368.1±29 – – – 
CSF total tau 
pg/mL(mean±SD) 
703.2±50 – – – 
CSF p-tau  
pg/mL(mean±SD) 
87.4±6 – – – 
CDR 0.8±0.8 – – – 
ADL 5.6±0.5 – – – 
IADL 7.5±0.5 – – – 
MMSE baseline 22.09±0.5 – – – 
Disease duration, 
m(mean±SD)a 
13.4±4.4 – – – 
E4 (E3/E4 + E4/E4) 
(%)b 
41 – – – 
21 
 
Table 2. Multivariable linear regression: relationship between TMS parameters, age and 
diagnosis of Alzheimer’s disease across all subjects.  
 
 
 
Abbreviations: iTBS= intermittent Theta Burst Stimulation; SE= standard error; CI= confidence 
interval; cTBS= continuous Theta Burst Stimulation; HS= healthy subjects; AD= Alzheimer’s disease; 
SAI= short-latency afferent inhibition. 
 
 
 
 
 
 
 
 
iTBS Coefficient SE p value CI 
HS/AD -51.49 6.16 <0.001* -63.76 – -39.22 
Age 0.32 0.49 0.51 -0.64 – 1.28 
cTBS 
    
HS/AD -1.34 5.97 0.82 -13.24 – 10.56 
Age -0.51 0.47 0.28 -1.44 – 0.42 
SAI 
    
HS/AD 10.83 5.31 0.04* 0.23 – 21.42 
Age 2.17 0.42 <0.001* 1.32 – 3.02 
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Table 3. Multivariable linear regression: relationship between TMS parameters, age, disease 
duration and cognitive decline in AD patients.  
 
 
 
 
Abbreviations: LTP= long term potentiation; SE= standard error; CI= confidence interval; MMSE= 
Mini Mental State Examination; SAI= short-latency afferent inhibition. 
 
iTBS Coefficient SE p value CI 
Age 0.62 0.52 0.23 -0.41 – 1.66 
Delta MMSE 1.46 0.65 0.03* 0.15 – 2.78 
disease duration -0.79 0.71 0.27 -2.22 – 0.64 
cTBS 
    
Age -1.01 0.54 0.08 -2.10 – 0.08 
Delta MMSE 0.15 0.69 0.83 -1.24 – 1.54 
disease duration -0.42 0.75 0.58 -1.93 – 1.09 
SAI 
    
Age 2.09 0.56 0.001* 0.96 – 3.22 
Delta MMSE 0.34 0.70 0.63 -1.07 – 1.75 
disease duration 0.09 0.75 0.89 -1.42 – 1.61 
